TickerFacts.

Company research / AUTL

Autolus Therapeutics plc (AUTL)

Build a valuation ↗↓ Download CSV

CIK 0001730463 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Autolus Therapeutics plc reported revenue of $75.39M. Revenue grew 644.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $117.39M.

Key ratios (year ended 2025-12-31)

-27.8%
Gross margin (computed)
-358.9%
Operating margin
-381.4%
Net margin
-161.4%
Return on year-end equity
644.9%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-03

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Revenue$117.39M$75.39M$10.12M$1.70Mn/an/an/an/an/an/an/a
Cost of Revenue$99.01M$96.37M$11.39M$0n/an/an/an/an/an/an/a
Gross Profit (computed)$18.38M-$20.98M-$1.27Mn/an/an/an/an/an/an/an/a
R&D Expense$112.63M$117.69M$138.44M$130.48Mn/an/an/a$117.35Mn/an/an/a
Operating Income-$247.44M-$270.54M-$241.43M-$179.70Mn/an/an/a-$143.41Mn/an/an/a
Depreciation & Amortization$8.59M$8.30M$7.55M$6.57Mn/an/an/a$7.42Mn/an/an/a
EBITDA-$238.85M-$262.25M-$233.87M-$173.14Mn/an/an/a-$135.99Mn/an/an/a
Net Income-$280.16M-$287.53M-$220.66M-$208.38Mn/an/an/a-$148.84Mn/an/an/a
EPS (Diluted)n/a-$1.08-$0.86-$1.20n/an/an/a-$1.57n/an/an/a
Total Assets$493.23M$589.07M$782.73M$375.38M$406.10M$450.99M$459.97M$490.27M$263.83M$313.98M$363.99M
Total Liabilities$418.39M$410.94M$355.40M$263.91M$225.58M$221.66M$193.05M$191.60M$102.68M$99.45M$92.85M
Shareholders' Equity$74.84M$178.13M$427.32M$111.47M$180.52M$229.34M$266.92M$298.67M$161.15M$214.52M$271.14M
Cash & Equivalents$171.41M$104.13M$227.38M$239.57M$256.42M$307.50M$343.03M$382.44M$163.05M$216.44M$268.56M
Operating Cash Flow-$225.61M-$283.57M-$206.27M-$145.59Mn/an/an/a-$112.31Mn/an/an/a
Capital Expenditures$7.12M$19.04M$22.07M$10.99Mn/an/an/a$10.84Mn/an/an/a
Free Cash Flow-$232.73M-$302.61M-$228.35M-$156.57Mn/an/an/a-$123.15Mn/an/an/a
Weighted Average Diluted Sharesn/a266.14M255.16M173.94Mn/an/an/a94.99Mn/an/an/a
EPS (Basic)n/a-$1.08-$0.86-$1.20n/an/an/a-$1.57n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView